Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 239.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,736 shares of the medical equipment provider's stock after acquiring an additional 28,042 shares during the period. Quantinno Capital Management LP's holdings in Zimmer Biomet were worth $4,197,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet in the fourth quarter worth $473,000. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet in the fourth quarter worth $7,825,000. Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Lmcg Investments LLC lifted its position in shares of Zimmer Biomet by 20.4% during the 4th quarter. Lmcg Investments LLC now owns 55,949 shares of the medical equipment provider's stock worth $5,910,000 after purchasing an additional 9,484 shares during the last quarter. Finally, MFG Wealth Management Inc. purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth $1,506,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent analyst reports. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Raymond James reduced their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, May 6th. JMP Securities decreased their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Barclays decreased their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $111.53.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.39% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH traded up $1.18 on Friday, reaching $92.85. The company's stock had a trading volume of 3,141,106 shares, compared to its average volume of 1,786,778. The stock's 50-day moving average is $101.84 and its two-hundred day moving average is $105.37. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $117.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $18.37 billion, a P/E ratio of 20.86, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business's revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.94 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.03%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.